Objective: We conducted a meta-analysis to assess the predictive value of CD276 expression in the clinicopathological features and prognosis of head and neck cancer.
Methods: Pubmed, Embase, Cochrane library, Web of science, CNKI and Wanfang databases were searched for studies focused on the role of CD276 expression in the clinicopathological features and prognosis of head and neck cancer, published up to December 2022. STATA 14.0 were used to perform the meta-analysis.
Results: A total of 8 eligible studies involving 1417 patients with head and neck cancer were included in this meta-analysis. The results showed that in terms of clinicopathological features, CD276 expression was related to gender [OR = 1.35, 95%CI = 1.01-1.82, P = 0.04], lymph node status [OR = 3.43, 95%CI = 1.96-5.98, P < 0.001] and TNM stage [OR = 2.54, 95%CI = 1.72-3.74, P < 0.001] of head and neck cancer patients, but not age [OR = 0.76, 95%CI = 0.52-1.11, P = 0.15] and tumor differentiation [OR = 1.39, 95%CI = 0.92-2.13, P = 0.12] . In terms of prognosis, CD276 expression is significantly associated with shorter overall survival [HR = 2.08, 95%CI = 1.22-3.56, P = 0.01] in head and neck cancer patients.
Conclusion: CD276 expression was significantly correlated with gender, lymph node status, TNM stage and poor prognosis in head and neck cancer patients and may be a new target for immunotherapy and a biomarker for predicting poor prognosis in head and neck cancer.
Keywords: CD276; Head and neck cancer; Meta-analysis; Prognosis.
Copyright © 2023 Elsevier Inc. All rights reserved.